Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113834
Chunk: 45

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 45
---
 validity of the securities offered hereby will be passed upon for us by DLA Piper LLP (US), Short Hills, New Jersey. Additional legal matters may be passed upon for any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement.

<div align='center'>EXPERTS</div>

The financial statements incorporated in this Prospectus by reference to theAnnual Report on Form 10-K for the year ended December 31, 2024have been so incorporated in reliance on the report of WithumSmith+Brown, PC, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

<div align='center'>33

________________________

$125,000,000

Common Stock

Preferred Stock

Debt Securities

Warrants

Rights

Units

________________________

PROSPECTUS

________________________

, 2025</div>

PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following table sets forth an itemization of the various expenses, all of which we will pay, in connection with the issuance and distribution of the securities being registered. All of the amounts shown are estimated except the SEC Registration Fee.

| SEC Registration Fee              |     | $ | 19,137.50 |
| Printing and Engraving Fees       |     |   |         * |
| Legal Fees and Expenses           |     |   |         * |
| Accounting Fees and Expenses      |     |   |         * |
| Transfer Agent and Registrar Fees |     |   |         * |
| Miscellaneous                     |     |   |         * |
| Total                             |     | $ |         * |

____________________

| * | These fees are calculated based on the type of securities offered and the number of issuances, which are indeterminable, and accordingly, cannot be estimated at this time. An estimate of the aggregate expenses in connection with the sale and distribution of securities being offered will be included in the applicable prospectus supplement. |

Item 15. Indemnification of Directors and Officers Section 102 of the Delaware General Corporation Law, or the DGCL, permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of